rc1416
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 3, 2023 (NCT06067490)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-4 receptor subunit alphaINHIBITOR
IL4R inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06911866 | Phase 1 | Oct 25, 2024 | RegeneCore |
| NCT06067490 | Phase 1 | Jul 3, 2023 | Peking University, RegeneCore |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RegeneCore | For profit | 2 | 2 | 1 | 2023 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1